Agios Pharmaceuticals, Inc. (AGIO)
$
27.61
-0.70 (-2.54%)
Key metrics
Financial statements
Free cash flow per share
-7.1224
Market cap
1.6 Billion
Price to sales ratio
35.9457
Debt to equity
0.0347
Current ratio
13.8196
Income quality
1.0216
Average inventory
31.4 Million
ROE
-0.2835
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing medicines within the realm of cellular metabolism and related biological areas. The company delivers pivotal treatments such as PYRUKYND (mitapivat), an activator for both wild-type and various mutant pyruvate kinase (PK) enzymes targeted at addressing hemolytic anemias. Additionally, Agios is advancing AG-946, currently in Phase I clinical studies for treating hemolytic anemias and other medical indications. Financially, the company earned an interest income of $48,083,000.00 showcasing its strategic financial investments. The income before tax ratio is 19.67 reflecting the pre-tax margin and indicating a robust operational capacity. However, the net total of other income and expenses is $1,143,706,000.00 which illustrates the influence of non-core financial activities on the overall financial picture. Moreover, the company reported depreciation and amortization expenses of $5,653,000.00 which reflect the wear and tear of its physical and intangible assets. The gross profit ratio is 0.89 indicating the efficiency of the company's production and sales operations in maintaining profitability while advancing its innovative drug portfolio. As a notable entity in the biopharmaceutical landscape, Agios Pharmaceuticals operates within a mid-range market capitalization of $1,610,044,349.00 positioning itself as a steady performer in the industry. The stock is affordable at $37.70 making it suitable for budget-conscious investors looking to engage in this sector. Additionally, the stock has an average trading volume of 1,664,188.00 indicating moderate liquidity, which is essential for investors considering market entry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape and driving forward innovation and growth. Positioned within the Healthcare sector, Agios Pharmaceuticals reflects a commitment to advancing healthcare solutions while fostering economic stability through its strategic investment and operational initiatives.
Is Agios Pharmaceuticals, Inc. (AGIO) a good investment?
Investing in Agios Pharmaceuticals, Inc. (AGIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Agios Pharmaceuticals, Inc. (AGIO)'s stock forecast?
Analysts predict Agios Pharmaceuticals, Inc. stock to fluctuate between $22.24 (low) and $46 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agios Pharmaceuticals, Inc.'s market capitalization?
As of 2026-01-30, Agios Pharmaceuticals, Inc.'s market cap is $1,610,044,349, based on 58,313,812 outstanding shares.
How does Agios Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agios Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agios Pharmaceuticals, Inc. (AGIO) stock?
To buy Agios Pharmaceuticals, Inc. (AGIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Agios Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Agios Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $36,498,000 | EPS: $11.86 | Growth: -287.36%.
Where can I find Agios Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.agios.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agios Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Agios Pharmaceuticals, Inc. stock?
All-time high: $62.58 (2024-11-11) | All-time low: $16.75 (2022-06-16).
What are the key trends affecting Agios Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
zacks.com
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
seekingalpha.com
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia is capped, with peak sales estimates around $500M, insufficient alone for profitability; SCD approval remains a major potential catalyst. AGIO maintains a strong cash position of $1.3B versus $101M in liabilities, providing ample runway for commercialization and further development.
zacks.com
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
fool.com
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the year.
reuters.com
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
globenewswire.com
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication AQVESME expected to be available in late January 2026, following AQVESME REMS program implementation Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass.
zacks.com
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
zacks.com
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
See all news
